IL95574A - Colestyramine preparation - Google Patents

Colestyramine preparation

Info

Publication number: IL95574A
Authority: IL; Israel
Prior art keywords: colestyramine; lipid; composition; lowering; preparation
Prior art date: 1989-09-09

Application number

IL9557490A

Other languages

English (en)

Other versions

IL95574A0 (en

Original Assignee

Knoll Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-09-09

Filing date

1990-09-04

Publication date

1994-11-11

1989-09-09 Priority claimed from DE19893930206 external-priority patent/DE3930206A1/de

1989-09-09 Priority claimed from DE3930168A external-priority patent/DE3930168A1/de

1990-09-04 Application filed by Knoll Ag filed Critical Knoll Ag

1991-06-30 Publication of IL95574A0 publication Critical patent/IL95574A0/xx

1994-11-11 Publication of IL95574A publication Critical patent/IL95574A/en

Links

229920001268 Cholestyramine Polymers 0.000 title claims abstract description 33
KNDHRUPPBXRELB-UHFFFAOYSA-M [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Chemical compound [Cl-].C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 KNDHRUPPBXRELB-UHFFFAOYSA-M 0.000 title claims abstract description 33
229960001678 colestyramine Drugs 0.000 title claims abstract description 33
238000002360 preparation method Methods 0.000 title abstract description 3
239000000203 mixture Substances 0.000 claims description 11
239000003524 antilipemic agent Substances 0.000 claims description 10
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims description 3
229960002297 fenofibrate Drugs 0.000 claims description 3
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 3
229960003627 gemfibrozil Drugs 0.000 claims description 3
150000002632 lipids Chemical class 0.000 abstract description 2
150000001875 compounds Chemical class 0.000 description 10
229940125753 fibrate Drugs 0.000 description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000002245 particle Substances 0.000 description 4
230000037396 body weight Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
229960000516 bezafibrate Drugs 0.000 description 2
IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
229960001214 clofibrate Drugs 0.000 description 2
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
239000008187 granular material Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000011324 bead Substances 0.000 description 1
229950009252 beclobrate Drugs 0.000 description 1
YWQGBCXVCXMSLJ-UHFFFAOYSA-N beclobrate Chemical compound C1=CC(OC(C)(CC)C(=O)OCC)=CC=C1CC1=CC=C(Cl)C=C1 YWQGBCXVCXMSLJ-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229960002174 ciprofibrate Drugs 0.000 description 1
KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229960003501 etofibrate Drugs 0.000 description 1
XXRVYAFBUDSLJX-UHFFFAOYSA-N etofibrate Chemical compound C=1C=CN=CC=1C(=O)OCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 XXRVYAFBUDSLJX-UHFFFAOYSA-N 0.000 description 1
201000001386 familial hypercholesterolemia Diseases 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
-1 flow regulators Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
231100000663 medical toxicology Toxicity 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000008016 pharmaceutical coating Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Sealing Battery Cases Or Jackets (AREA)
Laminated Bodies (AREA)

IL9557490A 1989-09-09 1990-09-04 Colestyramine preparation IL95574A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19893930206 DE3930206A1 (de)	1989-09-09	1989-09-09	Pharmazeutische erzeugnisse
DE3930168A DE3930168A1 (de)	1989-09-09	1989-09-09	Verbesserte verabreichungsform fuer colestyramin

Publications (2)

Publication Number	Publication Date
IL95574A0 IL95574A0 (en)	1991-06-30
IL95574A true IL95574A (en)	1994-11-11

Family

ID=25884990

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9557490A IL95574A (en)	1989-09-09	1990-09-04	Colestyramine preparation

Country Status (10)

Country	Link
EP (1)	EP0594570B1 (da)
JP (1)	JPH05500213A (da)
KR (1)	KR920703071A (da)
AT (1)	ATE125448T1 (da)
AU (1)	AU638493B2 (da)
CA (1)	CA2065151A1 (da)
DE (1)	DE59009451D1 (da)
DK (1)	DK0594570T3 (da)
IL (1)	IL95574A (da)
WO (1)	WO1991003249A1 (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
HU230253B1 (hu)	2001-01-26	2015-11-30	Merck Sharp & Dohme Corp	Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
DK1355644T3 (da)	2001-01-26	2006-10-23	Schering Corp	Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja)	2001-09-21	2005-02-10	シェーリング　コーポレイション	ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
WO2004043457A1 (en)	2002-11-06	2004-05-27	Schering Corporation	Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CA2517571C (en)	2003-03-07	2011-07-05	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja)	2003-03-07	2010-12-01	シェーリングコーポレイション	高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja)	2003-03-07	2006-08-31	シェーリング　コーポレイション	置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
ES2687027T3 (es)	2010-11-04	2018-10-23	Albireo Ab	Inhibidores de ibat para el tratamiento de enfermedades hepáticas
CN106659726A (zh)	2014-06-25	2017-05-10	Ea制药株式会社	固体制剂及其着色防止或着色减少方法
EP3012252A1 (en)	2014-10-24	2016-04-27	Ferring BV	Crystal modifications of elobixibat
CN108601739B (zh) *	2016-02-09	2022-01-04	阿尔比里奥公司	考来烯胺丸剂及其制备方法
ES2874669T3 (es)	2016-02-09	2021-11-05	Albireo Ab	Formulación oral de colestiramina y uso de la misma
WO2017138878A1 (en)	2016-02-09	2017-08-17	Albireo Ab	Oral cholestyramine formulation and use thereof
EP3664782B1 (en) *	2017-08-09	2025-01-29	Albireo AB	Cholestyramine pellets, oral cholestyramine formulations and medical use thereof
CN111032019B (zh)	2017-08-09	2022-07-05	阿尔比里奥公司	考来烯胺颗粒、口服考来烯胺制剂及其用途
CN112449637B (zh)	2018-06-05	2024-03-19	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US11801226B2 (en)	2018-06-20	2023-10-31	Albireo Ab	Pharmaceutical formulation of odevixibat
PL3810581T3 (pl)	2018-06-20	2025-04-28	Albireo Ab	Modyfikacje kryształu odewiksibatu
US11549878B2 (en)	2018-08-09	2023-01-10	Albireo Ab	In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en)	2018-08-09	2021-05-18	Albireo Ab	Oral cholestyramine formulation and use thereof
US10722457B2 (en)	2018-08-09	2020-07-28	Albireo Ab	Oral cholestyramine formulation and use thereof
CN118852054A (zh)	2019-02-06	2024-10-29	阿尔比里奥公司	苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
TWI835997B (zh)	2019-02-06	2024-03-21	瑞典商艾爾比瑞歐公司	苯并噻氮呯化合物及其用作膽酸調節劑之用途
ES2973355T3 (es)	2019-12-04	2024-06-19	Albireo Ab	Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
JP7696898B2 (ja)	2019-12-04	2025-06-23	アルビレオ・アクチボラグ	ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11014898B1 (en)	2020-12-04	2021-05-25	Albireo Ab	Benzothiazepine compounds and their use as bile acid modulators
EP4069247B1 (en)	2019-12-04	2025-03-26	Albireo AB	Benzothiadiazepine compounds and their use as bile acid modulators
IL293379B2 (en)	2019-12-04	2026-04-01	Albireo Ab	Benzothia(dia)azepine compounds and their use as bile acid modulators
EP4188541B1 (en)	2020-08-03	2024-12-25	Albireo AB	Benzothia(di)azepine compounds and their use as bile acid modulators
CA3196488A1 (en)	2020-11-12	2022-05-19	Albireo Ab	Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
BR112023010799A2 (pt)	2020-12-04	2023-10-03	Albireo Ab	Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
TW202313579A (zh)	2021-06-03	2023-04-01	瑞典商艾爾比瑞歐公司	苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1348642A (en) *	1970-10-15	1974-03-20	Howard A N	Hypocholesterolaemic compositions
GB1566609A (en)	1977-03-10	1980-05-08	Reckitt & Colmann Prod Ltd	Pharmaceutical compositions containing cholestyramine and alginic acid
EP0166315B1 (de)	1984-06-19	1989-08-23	BASF Aktiengesellschaft	Magensaftresistent überzogene zylindrische Pankreatin-Mikrotabletten
US4814354A (en)	1986-09-26	1989-03-21	Warner-Lambert Company	Lipid regulating agents
ZA876640B (en)	1986-09-26	1988-03-08	Warner-Lambert Company	Treated lipid regulator
CA1313135C (en) *	1987-02-09	1993-01-26	The Dow Chemical Company	Cholestyramine composition and process for its preparation
DE3869590D1 (de) *	1987-12-29	1992-04-30	Procter & Gamble	Mischung zur behandlung von hypercholesterolemie.
DE3808191C2 (de)	1988-03-11	1998-08-06	Astra Chem Gmbh	Colestyramin enthaltende pharmazeutische Zusammensetzung
US4931280A (en)	1988-06-13	1990-06-05	Basf K & F Corporation	Edible, baked compositions containing cholestyramine

1990
- 1990-09-04 IL IL9557490A patent/IL95574A/en not_active IP Right Cessation
- 1990-09-07 AT AT90913811T patent/ATE125448T1/de not_active IP Right Cessation
- 1990-09-07 CA CA002065151A patent/CA2065151A1/en not_active Abandoned
- 1990-09-07 AU AU64057/90A patent/AU638493B2/en not_active Ceased
- 1990-09-07 DK DK90913811.7T patent/DK0594570T3/da active
- 1990-09-07 JP JP2512849A patent/JPH05500213A/ja active Pending
- 1990-09-07 DE DE59009451T patent/DE59009451D1/de not_active Expired - Lifetime
- 1990-09-07 KR KR1019920700526A patent/KR920703071A/ko not_active Withdrawn
- 1990-09-07 EP EP90913811A patent/EP0594570B1/de not_active Expired - Lifetime
- 1990-09-07 WO PCT/EP1990/001514 patent/WO1991003249A1/de not_active Ceased

Also Published As

Publication number	Publication date
CA2065151A1 (en)	1991-03-10
ATE125448T1 (de)	1995-08-15
AU6405790A (en)	1991-04-08
WO1991003249A1 (de)	1991-03-21
EP0594570B1 (de)	1995-07-26
DE59009451D1 (de)	1995-08-31
IL95574A0 (en)	1991-06-30
KR920703071A (ko)	1992-12-17
DK0594570T3 (da)	1995-09-11
AU638493B2 (en)	1993-07-01
JPH05500213A (ja)	1993-01-21
EP0594570A1 (de)	1994-05-04

Legal Events

Date	Code	Title
1996-11-14	KB	Patent renewed
2001-01-11	KB	Patent renewed
2005-07-25	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
IL95574A (en)	1994-11-11	Colestyramine preparation
US5478578A (en)	1995-12-26	Powders for inhalation
CA2406373C (en)	2010-06-29	Controlled release paracetamol composition
RU2003126257A (ru)	2005-02-27	Твердая дозированная лекарственная форма для орального введения, содержащая комбинацию метформина и глибенкламида
UA29513C2 (uk)	2000-11-15	Фармацевтична композиція, що включає (е)-3,5-дигідрокси-7-[4'-4''-фторфеніл-2'-циклопропілхінолін-3'-іл]-6- гептенову кислоту
UA75047C2 (en)	2006-03-15	Fixed dose composition of levodopa, carbidopa and entacapone
EP1781277B1 (en)	2012-02-01	A combination composition comprising ibuprofen and paracetamol
GB2137496A (en)	1984-10-10	Use of fluoxetine as an anti-anxiety agent
EP0011490B1 (en)	1982-11-03	Analgesic tablet and process for its preparation
JP4853818B2 (ja)	2012-01-11	イブプロフェン及び塩酸アンブロキソール含有固形製剤
EP0689434B1 (en)	2002-08-07	Pharmaceutical compositions comprising paracetamol and l-cysteine or a precursor thereof
KR20040100835A (ko)	2004-12-02	안정된 제약및 갑상선 내분비 호르몬 구성물 및 그제조방법
US3197370A (en)	1965-07-27	Pyrilamine tannate compositions
WO1989007439A1 (en)	1989-08-24	Process for regulating the absorption rate of drugs and a pharmaceutical formulation
US3873709A (en)	1975-03-25	Method of treating psychosis
JPH06239763A (ja)	1994-08-30	感冒薬
RU2174836C1 (ru)	2001-10-20	Фармацевтическая композиция, обладающая анальгезирующим действием
JP2000229853A (ja)	2000-08-22	生理痛改善用組成物
CN107811983A (zh)	2018-03-20	一种托格列净组合物
KR830008678A (ko)	1983-12-14	진통 조성물
US3478151A (en)	1969-11-11	Compositions of perphenazine and protriptyline for treating mental disorders
JPS6360926A (ja)	1988-03-17	感冒薬
US2793157A (en)	1957-05-21	Anticonvulsant 3-ethyl-5-phenyl hydantoin unit dosages and method of using same
RU2200556C1 (ru)	2003-03-20	Лекарственная форма налтрексона
JPH06227995A (ja)	1994-08-16	安定化された固型製剤